https://doi.org/10.55788/810df2a6
“Resection of the primary tumour in patients with stage IV colorectal cancer is debated,” said
Prof. Jürgen Weitz (Technische Universität Dresden, Germany) at the start of his presentation [1]. It may prevent primary tumour complications, but increases the risk of surgical complications. Current evidence is unclear on whether the primary tumour should be resected in this population [2]. To address this gap in the literature, the SYNCHRONOUS trial (ISRCTN30964555) randomised 393 patients with colon cancer or high rectal cancer, synchronous metastases, and asymptomatic primary tumours to resection plus chemotherapy by physician’s choice or chemotherapy alone [1]. OS was the primary endpoint of this trial.
After a median follow-up of 36 months, no significant difference in OS was measured between the resection plus chemotherapy arm and the chemotherapy alone arm (16.7 vs 18.6 months; P=0.685). Notably, in a subgroup of patients that did not receive chemotherapy (24.1% in resection plus chemotherapy and 6.4% in chemotherapy alone arm), the OS decreased significantly (HR 5.32; P<0.001). In addition, no subgroup appeared to benefit from surgery in addition to chemotherapy in terms of OS.
Serious adverse events were more common in the chemotherapy arm (18.0% vs 10.2%), mainly due to an increased number of gastrointestinal tract-related events (10.7% vs 4.8%; P=0.031).
Prof. Weitz concluded that the addition of resection of the primary tumour to chemotherapy does not prolong OS in patients with colon cancer or high rectal cancer, asymptomatic primary tumours, and synchronous unresectable metastases. In fact, chemotherapy was the most important factor to impact the OS time of these patients.
- Rahbari NN, et al. Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. LBA3507, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.
- Cirocchi R, et al. Cochrane Database Syst Rev. 2012;8:CD008997.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Novel treatment option for KRAS wildtype pancreatic cancer Next Article
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases »
« Novel treatment option for KRAS wildtype pancreatic cancer Next Article
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases »
Table of Contents: ASCO 2022
Featured articles
Breast Cancer
Sacituzumab govitecan meets primary endpoint
Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer
Practice-changing results of T-DXd in HER2-low breast cancer
SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer
Metastasis-directed therapy fails in oligometastatic breast cancer
Analysis by residual cancer burden further clarifies effect of pembrolizumab
Contribution of metastatic therapies on mortality reduction in breast cancer
Radiotherapy may be omitted in breast cancer patients
Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups
Lung Cancer
Additional tiragolumab does not help patients with untreated small cell lung cancer
Success for serplulimab plus chemotherapy in small cell lung cancer
Adagrasib safe and clinically active in non-small cell lung cancer
Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer
Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer
Melanoma
First results on distant metastasis-free survival in stage II melanoma
Higher response rates for concurrent triple therapy versus sequential therapy in melanoma
Genitourinary Cancers
Exploratory treatment options fail in ccRCC
Adjuvant everolimus did not benefit high-risk renal cell carcinoma
Cabozantinib fails as first-line maintenance therapy in urothelial cancer
177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC
Enzalutamide performs well in metastatic hormone-sensitive prostate cancer
Haematologic Malignancies
Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma
Novel first-line treatment option for mantle cell lymphoma
Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma
Gastrointestinal Cancers
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases
To resect or not to resect primary tumours in stage IV colon cancer?
Novel treatment option for KRAS wildtype pancreatic cancer
Gynaecological Cancers
Primary results of rucaparib in ovarian cancer
Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer
Encouraging results of relacorilant in ovarian cancer
Miscellaneous Topics
Bacterial decolonisation effective against radiation dermatitis
New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma
Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma
Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy